Gain Therapeutics to Participate in ROTH Healthcare Conference
News related to:Gain Therapeutics, Inc · 1 min read
BETHESDA, Md., Sept. 17, 2026 /CourierPR/ -- Gain Therapeutics, Inc., a clinical-stage biotechnology company, will participate in the ROTH Fifth Annual Healthcare Opportunities Conference on September 29, 2026. The event, held at the Metropolitan Club in New York, NY, will feature a presentation by Gene Mack, the company’s President and CEO.
Mack will speak on the "Frontiers in Neuroscience" panel, scheduled for 11:00 a.m. Eastern Time. The presentation aims to highlight the company’s advancements in the discovery and development of allosteric small molecule therapies. Gain Therapeutics is currently evaluating its lead drug candidate, rexaceract, for the treatment of Parkinson’s disease, with or without a GBA1 mutation, in a Phase 1b clinical trial. The drug also holds potential for treating Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease.
Gain’s unique approach involves the use of its Magellan™ platform to discover novel allosteric small molecule modulators that can restore or disrupt protein function. This innovative method is expected to accelerate drug discovery and unlock novel disease-modifying treatments for a range of disorders, including neurodegenerative diseases, rare genetic disorders, and oncology.
The company’s pipeline includes multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors. Rexaceract, the lead drug candidate, is currently being evaluated for its efficacy in treating Parkinson’s disease, a condition that affects millions of people globally. The company’s ongoing research and development efforts are aimed at advancing the treatment of these challenging and often debilitating conditions.
Gain Therapeutics continues to face several challenges, including the need to replicate positive results from earlier preclinical studies and clinical trials. The company’s success in these areas will be crucial for the advancement of its drug candidates and the potential therapeutic and clinical benefits they offer.